Cargando…

Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study

OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ruohan, Lu, Guanyu, Lv, Zheng, Jia, Lin, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623315/
https://www.ncbi.nlm.nih.gov/pubmed/36330468
http://dx.doi.org/10.3389/fonc.2022.1048781
_version_ 1784821971044794368
author Yang, Ruohan
Lu, Guanyu
Lv, Zheng
Jia, Lin
Cui, Jiuwei
author_facet Yang, Ruohan
Lu, Guanyu
Lv, Zheng
Jia, Lin
Cui, Jiuwei
author_sort Yang, Ruohan
collection PubMed
description OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical characteristics of patients with VC and the prognosis by using different treatment options. METHODS: According to the 5th European School of Oncology (ESO)–European Society for Medical Oncology (ESMO) international consensus guidelines for advanced breast cancer guidelines (ABC 5), patients who were treated in the First Hospital of Jilin University from 2018 to 2022 and diagnosed with breast cancer VC were retrospectively analyzed. The analysis focused on the characteristics of the patients, the treatment regimens, and prognosis. RESULTS: A total of 133 patients were included in this study. As for metastasis breast cancer subtype, 92 (69.18%) were hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER-2) negative, 20 (15.04%) had HER-2 overexpression, and 21 (15.78%) were triple negative. All patients had an mOS of 11.2 months (range, 1.1–107.8 months). In different types of VC, the median overall survival (mOS) of bone marrow metastasis (BMM) was 18.0 months (range, 2.0–107.8 months), that of diffuse liver metastasis (DLM) was 8.1 months (range, 1.3–30.2 months), and that of meningeal metastasis (MM) was 9.0 months (range, 1.2–53.8 months). In 92 HR+, Her-2− patients using different treatment regimens, mOS was 6.2 months (range, 1.2–29.8 months) in the chemotherapy group while it was 24.3 months (range, 3.1–107.8 months) in the endocrine therapy (ET) group. Multivariate Cox regression analysis suggested that Eastern Cooperative Oncology Group (ECOG) scores and type of VC were associated with survival. CONCLUSION: Prognosis varied in different types of VC. Patients with BMM had the best prognosis, and DLM had the worst. As treatment options continue to progress, our retrospective study showed a significant prolongation of overall survival (OS) in patients with VC compared to previous studies.
format Online
Article
Text
id pubmed-9623315
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96233152022-11-02 Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study Yang, Ruohan Lu, Guanyu Lv, Zheng Jia, Lin Cui, Jiuwei Front Oncol Oncology OBJECTIVE: Breast cancer visceral crisis (VC) is caused by excessive tumor burden leading to severe organ dysfunction with poor prognosis. Traditional chemotherapy reduces the quality of life of patients without significantly improving survival. The aim of this study was to investigate the clinical characteristics of patients with VC and the prognosis by using different treatment options. METHODS: According to the 5th European School of Oncology (ESO)–European Society for Medical Oncology (ESMO) international consensus guidelines for advanced breast cancer guidelines (ABC 5), patients who were treated in the First Hospital of Jilin University from 2018 to 2022 and diagnosed with breast cancer VC were retrospectively analyzed. The analysis focused on the characteristics of the patients, the treatment regimens, and prognosis. RESULTS: A total of 133 patients were included in this study. As for metastasis breast cancer subtype, 92 (69.18%) were hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER-2) negative, 20 (15.04%) had HER-2 overexpression, and 21 (15.78%) were triple negative. All patients had an mOS of 11.2 months (range, 1.1–107.8 months). In different types of VC, the median overall survival (mOS) of bone marrow metastasis (BMM) was 18.0 months (range, 2.0–107.8 months), that of diffuse liver metastasis (DLM) was 8.1 months (range, 1.3–30.2 months), and that of meningeal metastasis (MM) was 9.0 months (range, 1.2–53.8 months). In 92 HR+, Her-2− patients using different treatment regimens, mOS was 6.2 months (range, 1.2–29.8 months) in the chemotherapy group while it was 24.3 months (range, 3.1–107.8 months) in the endocrine therapy (ET) group. Multivariate Cox regression analysis suggested that Eastern Cooperative Oncology Group (ECOG) scores and type of VC were associated with survival. CONCLUSION: Prognosis varied in different types of VC. Patients with BMM had the best prognosis, and DLM had the worst. As treatment options continue to progress, our retrospective study showed a significant prolongation of overall survival (OS) in patients with VC compared to previous studies. Frontiers Media S.A. 2022-10-18 /pmc/articles/PMC9623315/ /pubmed/36330468 http://dx.doi.org/10.3389/fonc.2022.1048781 Text en Copyright © 2022 Yang, Lu, Lv, Jia and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Ruohan
Lu, Guanyu
Lv, Zheng
Jia, Lin
Cui, Jiuwei
Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title_full Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title_fullStr Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title_full_unstemmed Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title_short Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
title_sort different treatment regimens in breast cancer visceral crisis: a retrospective cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623315/
https://www.ncbi.nlm.nih.gov/pubmed/36330468
http://dx.doi.org/10.3389/fonc.2022.1048781
work_keys_str_mv AT yangruohan differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy
AT luguanyu differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy
AT lvzheng differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy
AT jialin differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy
AT cuijiuwei differenttreatmentregimensinbreastcancervisceralcrisisaretrospectivecohortstudy